Cost of patient follow-up after potentially curative lung cancer treatment

J Thorac Cardiovasc Surg. 1996 Aug;112(2):356-63. doi: 10.1016/S0022-5223(96)70262-3.

Abstract

The two objectives of this study were to determine the range of recommended follow-up strategies for patients with lung cancer treated with curative intent and to estimate the cost of such follow-up. Ten articles delineating eight specific follow-up strategies were identified from a Medline search of the literature for 1980 through 1995. An economic analysis was done of the costs associated with the identified strategies. Charge data obtained from the Part B Medicare Annual Data file and the Hospital Outpatient Bill file were used as a proxy for cost. Follow-up intensity varied widely across strategies for 5 years of posttreatment follow-up. Medicare-allowed charges for 5-year follow-up ranged from a low of $946 to a high of $5645. When Medicare-allowed charges were converted to a proxy for actual charges by a conversion ratio of 1.62, the range was $1533 to $9145, a fivefold difference in charges. There was no indication that more intensive, higher-cost strategies increased survival or quality of life. The published literature, including textbooks, holds few answers in this area.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Blood Chemical Analysis / economics
  • Clinical Laboratory Techniques / economics
  • Cohort Studies
  • Costs and Cost Analysis
  • Follow-Up Studies
  • Hospital Charges
  • Hospital Costs
  • Humans
  • Lung Neoplasms / economics*
  • Lung Neoplasms / therapy*
  • Medicare / economics
  • Medicare Part B / economics
  • Neoplasm Recurrence, Local
  • Neoplasms, Second Primary / economics
  • Neoplasms, Second Primary / therapy
  • Office Visits / economics
  • Prospective Studies
  • Quality of Life
  • Radiography, Thoracic / economics
  • Retrospective Studies
  • Sputum
  • United States